Orthocell (ASX:OCC) secured approval to market and sell its Remplir nerve repair collagen wrap from the Singaporean Health Science Authority, according to a Tuesday filing with the Australian bourse.
This is the first approval for the device outside of Australia and New Zealand in a country considered to be the gateway for the ASEAN market, the filing said.
The device is expected to be distributed to the Singaporean market by the first quarter of next year, as per the filing.
The company's shares rose past 5% in recent Tuesday trade and earlier hit their highest level since May 2021.
Price (AUD): $0.51, Change: $+0.03, Percent Change: +5.21%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.